Treatment Overview
Post-TURBT bladder instillation is an intravesical therapy administered immediately after a transurethral resection of bladder tumor (TURBT) procedure to prevent recurrence of non-muscle invasive bladder cancer (NMIBC). The therapy typically involves chemotherapeutic agents such as Mitomycin C, Epirubicin, or Gemcitabine, delivered directly into the bladder via a catheter. Korea is globally recognized for its expertise in post-TURBT instillation, offering precise drug administration, advanced cystoscopic guidance, and close patient monitoring to ensure maximum efficacy and safety for both local and international patients.
Purpose & Benefits
The primary purpose of post-TURBT bladder instillation is to eliminate residual cancer cells in the bladder immediately after tumor removal, reducing the risk of recurrence. Benefits include:
- Immediate treatment targeting microscopic residual tumor cells
- Reduced recurrence rates for NMIBC patients
- Preservation of bladder function and overall quality of life
- Short outpatient procedure with rapid recovery
- Can be combined with sequential or maintenance intravesical therapy for enhanced outcomes
Korean hospitals personalize therapy protocols based on tumor characteristics, patient health, and prior treatment history to achieve optimal results.
Ideal Candidates
Ideal candidates include:
- Patients undergoing TURBT for NMIBC
- Individuals at low to intermediate risk of recurrence
- Patients seeking bladder preservation over radical cystectomy
- Medically suitable patients who can tolerate intravesical chemotherapy
Patients with active urinary tract infections, bladder perforation, or allergies to the chemotherapeutic agent require careful assessment. Korean specialists perform thorough evaluations before starting therapy.
Possible Risks & Complications
Post-TURBT bladder instillation is generally safe, but potential risks include:
- Mild bladder irritation, urgency, and frequency
- Painful urination (dysuria)
- Hematuria (blood in urine)
- Rare chemical cystitis or bladder inflammation
- Minimal systemic effects such as fatigue
Korean hospitals minimize risks by carefully controlling drug concentration, dwell time, and monitoring during and after instillation.
Techniques & Technology Used
Korean hospitals employ advanced techniques to maximize safety and efficacy:
- Cystoscopic-guided catheter placement for accurate drug delivery
- Immediate post-TURBT instillation protocols to target residual tumor cells
- Controlled dwell times to ensure full bladder wall exposure
- Follow-up cystoscopy and urine cytology to monitor treatment response
- Personalized treatment adjustments based on patient tolerance and risk
These techniques ensure precise treatment with minimal discomfort and high effectiveness.
Treatment Process in Korea
The treatment process for international patients includes:
- TURBT procedure to remove visible tumors
- Immediate post-TURBT bladder instillation in the same session or within 24 hours
- Monitoring for adverse effects during and after instillation
- Scheduled follow-up cystoscopies to assess recurrence
- Additional intravesical therapy if indicated, including sequential or maintenance therapy
- Patient education on bladder care, hydration, and symptom monitoring
Multilingual patient coordinators assist with scheduling, logistics, and aftercare instructions.
Recovery & After-Care
Recovery is rapid since post-TURBT instillation is minimally invasive. Aftercare includes:
- Retaining the instillation in the bladder for the prescribed dwell time (typically 1–2 hours)
- Drinking plenty of fluids to reduce bladder irritation
- Avoiding sexual activity or strenuous activity during dwell time
- Monitoring for urinary symptoms such as hematuria or dysuria
- Attending follow-up cystoscopies for early detection of recurrence
Telemedicine support is often available for international patients after returning home.
Results & Longevity
Post-TURBT bladder instillation in Korea has proven effective in reducing NMIBC recurrence rates, especially in low- and intermediate-risk patients. Most patients retain bladder function, experience minimal systemic side effects, and return to daily activities quickly. Structured follow-up ensures long-term monitoring and early intervention if necessary.
Why Korea Is a Top Destination
Korea is preferred for post-TURBT bladder instillation therapy due to:
- Expertise in NMIBC management and intravesical chemotherapy
- Advanced cystoscopic guidance and immediate instillation protocols
- Integration with TURBT for comprehensive tumor management
- Efficient outpatient scheduling and minimal waiting times
- Multilingual support and care coordination for international patients
- Cost-effective treatment compared with Western countries without compromising quality
Patients benefit from world-class care, precise therapy, and structured follow-up programs.
Cost Range
The cost of post-TURBT bladder instillation therapy in Korea generally ranges from USD 1,500 to USD 4,000 per treatment cycle, depending on:
- Type of instillation agent used
- Hospital category and facility fees
- Combination with additional TURBT or follow-up imaging
- Follow-up cystoscopies and monitoring
Hospitals provide transparent packages for international patients covering all essential steps.
Popular Clinics in Korea
- Asan Medical Center – Urology & Bladder Cancer Clinic
- Seoul National University Hospital – NMIBC Treatment Program
- Samsung Medical Center – Post-TURBT Instillation Unit
- Severance Hospital (Yonsei University) – Bladder Cancer Center
- Korea University Anam Hospital – Outpatient Uro-Oncology Clinic
- Seoul St. Mary’s Hospital – Post-TURBT Therapy & Monitoring Clinic
